Viewing Study NCT06776757


Ignite Creation Date: 2025-12-24 @ 6:48 PM
Ignite Modification Date: 2026-01-04 @ 6:03 PM
Study NCT ID: NCT06776757
Status: RECRUITING
Last Update Posted: 2025-01-15
First Post: 2025-01-10
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module